Interferon plus amantadine versus interferon alone in the treatment of naı̈ve patients with chronic hepatitis C: a UK multicentre study
- 31 October 2001
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 35 (4), 512-516
- https://doi.org/10.1016/s0168-8278(01)00140-4
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and CirrhosisNew England Journal of Medicine, 2000
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- EASL International Consensus Conference on Hepatitis CParis, 26–27 February 1999Consensus StatementJournal of Hepatology, 1999
- Global surveillance and control of hepatitis CJournal of Viral Hepatitis, 1999
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- Treatment of Chronic Hepatitis C with AmantadineDigestive Diseases and Sciences, 1997
- Meta–Analysis of Interferon Randomized Trials in the Treatment of Viral Hepatitis C: Effects of Dose and DurationHepatology, 1996
- Clinical Outcomes after Transfusion-Associated Hepatitis CNew England Journal of Medicine, 1995
- Inhibition of dengue virus replication by amantadine hydrochlorideAntimicrobial Agents and Chemotherapy, 1980